Healthcare - Biotechnology - NASDAQ - US
$ 3.54
1.43 %
$ 38.2 M
Market Cap
-1.99
P/E
CASH FLOW STATEMENT
-14.3 M
OPERATING CASH FLOW
-930 K
INVESTING CASH FLOW
-500 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Lantern Pharma Inc.
| Net Income | -16 M |
| Depreciation & Amortization | 175 K |
| Capital Expenditures | -18.7 K |
| Stock-Based Compensation | 1.07 M |
| Change in Working Capital | 538 K |
| Others | 373 K |
| Free Cash Flow | -14.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (16.0) | (14.3) | (12.4) | (5.9) | (2.4) | (1.7) |
| Depreciation & Amortization | 0.2 | 10.1 K | 6.76 K | 3.39 K | 1.63 K | 2.54 K |
| Deferred Income Tax | 0 | 0 | 0.1 | (1.1) | 0.3 | 0 |
| Stock Based Compensation | 1.1 | 1.2 | 1.0 | 1.2 | 0.1 | 0.2 |
| Other Operating Activities | (0.2) | 0.9 | 90.7 K | 1.1 | (0.3) | 76.3 K |
| Change in Working Capital | 0.5 | (0.6) | 0.6 | (0.9) | 0.2 | 0.3 |
| Cash From Operations | (14.3) | (12.8) | (10.6) | (5.7) | (2.1) | (1.3) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 18.7 K | 27.8 K | 15.5 K | 16.1 K | 5.72 K | 0 |
| Other Items | (0.9) | 0.2 | (19.5) | 0 | 0 | 5.34 K |
| Cash From Investing Activities | (0.9) | 0.2 | (19.5) | 16.1 K | 5.72 K | 5.34 K |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (0.5) | (2.5) | (0.9) | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0.1 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (2.5) | (5.6) | 26.2 | 2.9 | 0.5 |
| Cash From Financing Activities | (0.5) | 2.18 K | 63.4 | 23.7 | 2.9 | 0.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (15.8) | (14.8) | 33.3 | 18.0 | 0.8 | (0.7) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (14.4) | (12.8) | (10.6) | (5.7) | (2.1) | (1.3) |